Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1692410 | 0.85 | MEN1 (0.37) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL906190 | 0.84 | SMPD1 (0.37) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Hydrochloric Acid SCHEMBL17143222 | 0.82 | LMNA (0.38) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL14739090 | 0.81 | MEN1 (0.35) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL8160112 | 0.81 | SMPD1 (0.45) | MEN1KMT2ACYP2C19CYP1A2SLC25A20 | |
| SCHEMBL5255308 | 0.80 | MEN1 (0.34) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL14739986 | 0.80 | GABBR2 (0.36) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL3503898 | 0.80 | MEN1 (0.34) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL6130068 | 0.80 | MEN1 (0.33) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL62053 | 0.80 | SMPD1 (0.47) | MEN1KMT2ACYP2C19SLC25A20TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 996 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144751-A1 | LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOF | PHARMOSA BIOPHARM INC. (TW) | 2026-05-28 | — | — | US | claimed |
| US-20260097095-A1 | PEGYLATED RECONSTITUTED HIGH-DENSITY LIPOPROTEIN NANOPARTICLES | MEPSGEN CO LTD (KR) | 2026-04-09 | — | — | US | claimed |
| US-20260069535-A1 | NEBULIZER KITS AND USES THEREOF | PHARMOSA BIOPHARM INC (TW) | 2026-03-12 | — | — | US | claimed |
| EP-4706644-A1 | RECONSTITUTED HIGH-DENSITY LIPOPROTEIN NANOPARTICLES COMPRISING CHOLESTEROL | Mepsgen Co., Ltd. (KR) | 2026-03-11 | — | — | EP | claimed |
| EP-4706645-A1 | PEGYLATED RECONSTITUTED HIGH-DENSITY LIPOPROTEIN NANOPARTICLES | Mepsgen Co., Ltd. (KR) | 2026-03-11 | — | — | EP | claimed |
| US-12551437-B2 | Liposome compositions comprising weak acid drugs and uses thereof | PHARMOSA BIOPHARM INC. (TW) | 2026-02-17 | — | — | US | claimed |
| EP-4691619-A1 | MICROFLUIDIC DEVICE FOR MANUFACTURING UNIFORM NANOPARTICLES | Mepsgen Co., Ltd. (KR) | 2026-02-11 | — | — | EP | claimed |
| US-20260021485-A1 | MICROFLUIDIC DEVICE FOR MANUFACTURING UNIFORM NANOPARTICLES | MEPSGEN CO LTD (KR) | 2026-01-22 | — | — | US | claimed |
| WO-2025230917-A1 | METHODS FOR TREATING SYSTEMIC SCLEROSIS AND FROST BITE BY INHALATION THERAPY | PHARMOSA BIOPHARM INC. (TW) | 2025-11-06 | — | — | WO | claimed |
| US-20250288688-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | RECODE THERAPEUTICS, INC. | 2025-09-18 | — | — | US | claimed |
| EP-1626728-A2 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | Vascular Biogenics Ltd. (IL) | 2006-02-22 | — | — | EP | claimed |
| WO-2006006161-A2 | IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | VASCULAR BIOGENICS LTD. (IL) | 2006-01-19 | — | — | WO | claimed |
| US-20050107287-A1 | Treatment of cancers by inhalation of stable platinum-containing formulations | PILKIEWICZ FRANK G (US) | 2005-05-19 | — | — | US | claimed |
| EP-1305322-A4 | DERIVATIVES OF BRANCHED-CHAIN LIPOPHILIC MOLECULES AND USES THEREOF | DPHARM LTD (IL) | 2005-04-13 | — | — | EP | claimed |
| WO-2004106486-A2 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | VASCULAR BIOGENICS LTD. (IL) | 2004-12-09 | — | — | WO | claimed |
| JP-2004505898-A | — | — | 2004-02-26 | — | — | JP | claimed |
| EP-1305322-A2 | DERIVATIVES OF BRANCHED-CHAIN LIPOPHILIC MOLECULES AND USES THEREOF | D-Pharm Ltd. (IL) | 2003-05-02 | — | — | EP | claimed |
| WO-2002011666-A2 | DERIVATIVES OF BRANCHED-CHAIN LIPOPHILIC MOLECULES AND USES THEREOF | D-PHARM LTD. (IL) | 2002-02-14 | — | — | WO | claimed |
| EP-1049491-A1 | GENE THERAPY OF TUMORS USING NON-VIRAL DELIVERY SYSTEM | Perez-Soler, Roman (US) | 2000-11-08 | — | — | EP | claimed |
| WO-1999034835-A1 | GENE THERAPY OF TUMORS USING NON-VIRAL DELIVERY SYSTEM | PEREZ SOLER ROMAN (US) | 1999-07-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288688-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | LIPA, AUP1, PLIN3 | MEN1 2707/4885KMT2A 4230/4885CYP2C19 1455/4885 |
| US-20260021485-A1 | MICROFLUIDIC DEVICE FOR MANUFACTURING UNIFORM NANOPARTICLES | CD44, CAD, SLCO4C1 | MEN1 345/4885KMT2A 4106/4885CYP2C19 861/4885 |
| US-20260069535-A1 | NEBULIZER KITS AND USES THEREOF | PTGER2, PTGER1, PTGIR | MEN1 2924/4885KMT2A 4795/4885CYP2C19 443/4885 |
| US-20260144751-A1 | LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOF | LIPA, NSF, SLC26A3 | MEN1 1102/4885KMT2A 1667/4885CYP2C19 260/4885 |
| US-20260097095-A1 | PEGYLATED RECONSTITUTED HIGH-DENSITY LIPOPROTEIN NANOPARTICLES | LDLR, CETP, APOL1 | MEN1 3896/4885KMT2A 2795/4885CYP2C19 519/4885 |
| US-12551437-B2 | Liposome compositions comprising weak acid drugs and uses thereof | SLC26A3, LIPA, NSF | MEN1 1976/4885KMT2A 2246/4885CYP2C19 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.